



Psychophysical and vasomotor evidence for interdependency of TRPA1 and TRPV1-evoked nociceptive responses in human skin

an experimental study

Nielsen, Thomas Arendt; Eriksen, Matilde Alida; Gazerani, Parisa; Andersen, Hjalte Holm

Published in:
Pain

DOI (link to publication from Publisher):
[10.1097/j.pain.0000000000001298](https://doi.org/10.1097/j.pain.0000000000001298)

Publication date:
2018

Document Version
Accepted author manuscript, peer reviewed version

[Link to publication from Aalborg University](#)

Citation for published version (APA):

Nielsen, T. A., Eriksen, M. A., Gazerani, P., & Andersen, H. H. (2018). Psychophysical and vasomotor evidence for interdependency of TRPA1 and TRPV1-evoked nociceptive responses in human skin: an experimental study. *Pain*, 159(10), 1989–2001. <https://doi.org/10.1097/j.pain.0000000000001298>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal -

Take down policy

If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to the work immediately and investigate your claim.

Psychophysical and vasomotor evidence for interdependency of TRPA1 and TRPV1 nociceptive responses in human skin: an experimental study
(revised manuscript - PAIN-D-18-00060 R1)

Running title: TRPA1 and TRPV1 interactions in human skin

Thomas Arendt Nielsen^{1,2}, Matilde Alida Eriksen^{1,2}, Parisa Gazerani¹, Hjalte Holm Andersen^{1*}

¹Laboratory of Experimental Cutaneous Pain and Itch Research, Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Aalborg, Denmark

² Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Denmark

*Corresponding author:

Hjalte Holm Andersen

SMI[®], Department of Health Science and Technology

Fredrik Bajers Vej 7A, A2-203

Faculty of Medicine, Aalborg University

DK – 9220 Aalborg E, Denmark

Tel.: +45 24 46 45 15 / E-mail: hha@hst.aau.dk

Conflict of Interest and Source of Funding: No conflicts of interest.

Number of pages: 25 (all inclusive)

Number of figures: 7

Number of tables: 1

Statement of exclusivity: This manuscript is submitted only to *PAIN* and has not previously been published.

Contributions: HHA conceived the initial research idea. TAN, MAE, PG and HHA designed the study. TAN and MAE collected the data. TAN, MAE and HHA analyzed the data. TAN and MAE drafted the

initial manuscript. All authors commented on the analysis and manuscript. All authors approved the final manuscript.

Author statement: All authors read and approved the manuscript.

Abstract

The TRPA1 and TRPV1 receptors are important pharmaceutical targets for antipruritic and analgesic therapy. Obtaining further knowledge on their roles and inter-relationship in humans is therefore crucial. Preclinical results are contradictory concerning co-expression and functional interdependency of TRPV1 and TRPA1 but no human evidence exists. This human experimental study investigated whether functional responses from the subpopulation of TRPA1⁺-nociceptors could be evoked following defunctionalization of TRPV1⁺-nociceptors by cutaneous application of high-concentration capsaicin. Two quadratic areas on each forearm were randomized to pretreatment with an 8% topical capsaicin patch or vehicle for 24h. Subsequently, areas were provoked by transdermal 1% topical capsaicin (TRPV1 agonist) or 10% topical allyl-isothiocyanate ('AITC', a TRPA1-agonist), delivered by 12mm Finn chambers. Evoked pain intensities were recorded during pretreatments and chemical provocations. Quantitative sensory tests were performed before and after provocations to assess changes of heat pain sensitivity. Imaging of vasomotor responses was used to assess neurogenic inflammation after the chemical provocations. In the capsaicin-pretreated areas both the subsequent 1% capsaicin- and 10% AITC-provoked pain intensities were inhibited by 92.9±2.5% and 86.9±5.0% (both: P<0.001), respectively. The capsaicin-ablated skin areas showed significant heat hypoalgesia at baseline (P<0.001) as well as heat antihyperalgesia, and inhibition of neurogenic inflammation evoked by both 1% capsaicin- and 10% AITC provocations (both: P<0.001). Ablation of capsaicin-sensitive afferents caused consistent and equal inhibition of both TRPV1 and TRPA1-provoked responses assessed psychophysically and by imaging of vasomotor responses. The present study suggests that TRPA1 nociceptive responses in human skin strongly depend on intact capsaicin-sensitive, TRPV1⁺ fibers.

Key words: Capsaicin, AITC, Mustard oil, TRPV1, TRPA1, Neurogenic inflammation, Hyperalgesia

Article category: Original research manuscript

1 **1. Introduction**

2 A variety of receptors are expressed by cutaneous nociceptors (C- and A δ -fibers). Key transducers
3 include the transient receptor potential vanilloid 1 (TRPV1) and ankyrin 1 (TRPA1), both of which are
4 members of the TRP ion-channel superfamily⁴⁵. TRPA1 and V1 are activated by various algogens and
5 noxious stimuli, and much GPCR-detected nociceptive and pruriceptive signaling co-opts these channels.
6 In particular, TRPA1 is required for non-histaminergic itch, as multiple histamine-independent itch
7 transduction pathways involve TRPA1 co-activation⁸⁸. TRPA1 is also involved in pain as well as
8 inflammation of the skin, airways and gastrointestinal tract, acting both as an inflammatory instigator and
9 a detector of various inflammatory mediators^{19,67}. TRPA1-signalling has been implicated in a diverse
10 range of diseases including migraine²⁸, diabetic neuropathy⁴⁸ as well as atopic dermatitis, where lesional
11 skin areas exhibit highly increased expression^{60,63}.

12

13 While capsaicin activates TRPV1, allyl isothiocyanate (AITC), also known as mustard oil (MO) activates
14 TRPA1¹⁰. TRPV1 is evidently more densely expressed in rodent dorsal root ganglion (DRG) nociceptors
15 than TRPA1 but the two receptors do exhibit substantial co-expression. However, it remains unclear
16 whether a functionally significant subpopulation of TRPA1⁺ but TRPV1⁻ nociceptors exists. Following
17 the initial discovery of TRPA1, rodent studies showed an almost complete DRG co-expression of TRPV1
18 and TRPA1 mRNA⁸¹. Using calcium imaging in rat trigeminal ganglia, AITC-responsiveness was shown
19 in 35% of the neurons, while capsaicin excited 55%, including all of the AITC-responsive cells⁴¹.

20 Contrasting these findings, several recent rodent studies using, e.g., back-labeling of cutaneous afferents
21 and unbiased single cell RNA sequencing have suggested that TRPA1⁺ nociceptors, which do not express
22 TRPV1 are much more common than previously assumed^{37,51,56,82,85}. As such the expressional patterns of
23 TRP-channels in nociceptive DRG neurons and on peripheral nociceptors and in particular, the functional
24 overlap between TRPA1 and V1 in the nociceptive system of rodents remain unknown. Moreover, despite
25 substantial inter-specie differences in somatosensory processing²², no attempts have been conducted to
26 assess TRPA1/V1 interactions human skin and in particular whether TRPA1-induced responses are
27 predominantly TRPV1-dependent. Due to the significant pathophysiological implications of TRPA1 and
28 TRPV1, e.g., in pain and itch conditions, development of selective TRPA1 and V1-antagonists are being
29 actively pursued for instance as novel analgesics and antipruritics. Acquiring further knowledge regarding
30 the functional interdependency of TRPA1/V1 is therefore important for drug development, early phase
31 testing, and potential evaluation of disease indications.

32

33

1 Administration of 8% topical capsaicin (Qutenza™) can drastically defunctionalize human TRPV1⁺
2 nociceptive cutaneous afferents^{4,9,43,61}, thus enabling investigation of sensory and vasomotor responses in
3 absence of this significant proportion of nociceptors^{9,35}. This randomized, double-blinded, vehicle-
4 controlled study aimed to evaluate the extent of the functional overlap between the TRPA1 and TRPV1 in
5 healthy human skin, by comparatively assessing pain, heat pain sensitivity, and neurogenic inflammation
6 evoked by capsaicin and AITC in skin areas pretreated with topical 8% capsaicin. Based on recent rodent
7 studies, we hypothesized that prolonged 8% capsaicin-pretreatment would result in a complete abolition
8 of TRPV1-evoked responses, but only a moderate reduction in TRPA1-evoked responses, reflecting a
9 substantial, but incomplete, functional overlap between the two nociceptor populations in human skin.

11 2. Methods

13 2.1. Participants and study design

14 Eighteen healthy subjects (9M/9F, aged 28 ± 7 years (mean \pm SD)) were recruited. Subjects were pain-
15 free, without previous known dermatological, allergic, musculoskeletal, neurological, or psychiatric
16 disorders. Subjects were instructed to abstain from alcohol and medication 24 h prior to all sessions.
17 Before participating in the study, all subjects signed a statement of informed consent in accordance with
18 the 2013 Helsinki Declaration. The regional ethics committee approved the experimental protocol (study
19 no. N-20170018). The study was carried out in a vehicle-controlled, double-blinded manner with
20 balanced randomization of the placement of pretreatment (vehicle vs. 8% capsaicin), provocation
21 compounds (10% AITC and 1% capsaicin) as well as the order of provocation tests. The study was
22 conducted in three sessions with inter-session intervals of 24 h (see Fig. 1A). In session 1, patches were
23 applied, in session 2 patches were removed and in session 3, provocation compounds were applied, and
24 sensory as well as vasomotor responses were assessed. The investigator conducting the psychophysical
25 tests in session 3 was blinded with respect to treatment. Therefore, Investigator A conducted session 1 and
26 2, and Investigator B conducted session 3 or vice versa. All sessions were conducted using a standardized
27 script, in order to minimize information/observer bias.

29 2.2. Application of 8% capsaicin and vehicle patch (pretreatment)

30 A total of four squared areas (A1-A4), measuring 4x4cm, were marked on the volar forearms of all
31 subjects (see Fig. 1B). Each area was treated in a block-randomized manner with a patch (4x4 cm)
32 containing either 8% capsaicin (Qutenza, Astellas Pharma A/S, Kastrup, Denmark) or vehicle (Qutenza
33 Demo patch, Astellas Pharma). The patches were placed 4 cm apart to blind the subjects (taking
34 advantage of the poor spatial resolution of cutaneous chemesthesis (previously estimated to be

1 approximately 15 cm on the longitudinal axis of the volar forearm in healthy controls) while ensuring that
2 neurogenic inflammatory reactions evoked in the 3rd session would not overlap. Furthermore, unblinding
3 caused by identification of primary and secondary capsaicin-evoked neurogenic inflammation, were
4 avoided by masking patches using non-transparent medical tape. This approach has been applied in a
5 previous study using a similar 8% capsaicin ablation method ⁹. Following the application of patches in
6 session 1, subjects rated the pain intensity on each arm, once every hour, for six hours. This was done
7 using a numerical rating scale (NRS₀₋₁₀; "no pain" = 0 to "worst imaginable pain" = 10). Then, 24 h later,
8 subjects rated the average and peak pain scores experienced during the 24 h. Robust defunctionalization
9 of TRPV1⁺ epidermal fibers is known to be induced by 24 h application of 8% capsaicin ⁹; hence, patches
10 were left for 24 h before being removed during session 2. After patch removal, the participants were
11 asked if they could identify the active patch area, to get an estimate of the successfulness of the blinding
12 procedure.

13

14 **2.3. Quantitative sensory testing (QST)**

15 In session 3, heat pain thresholds (HPT) and suprathreshold heat pain sensitivity (SHPS) were assessed
16 using a Medoc Pathway (Medoc Ltd, Ramat Yishay, Israel) equipped with a 3x3 cm stimulator probe
17 with the aim of assessing the development of heat hyperalgesia. This was done to assess changes in heat
18 pain sensitivity evoked by the pretreatment and provocation compounds. All sensory tests were performed
19 as three consecutive stimuli to the treated areas (A1-A4, Fig. 1B). The provocation order and anatomical
20 locations were randomized. Hence, if A1 was determined to be the first area for provocation compound
21 application, this was also the first area in which sensory testing were performed. Sensory testing was
22 performed in all 4 areas immediately before moving on to provocation compound administration. This
23 was done in order to ensure that all measurements had the same time from pre-HPT/STHP to substance
24 administration (provocation).

25

26 Heat pain thresholds were measured using a ramping stimuli of 1°C/s from a baseline temperature of
27 32°C, with a cut-off of 52°C and with 5s inter-stimulus intervals based on standardized QST protocols
28 ^{69,70}. As soon as the subjects sensed the warmth sensation becoming painful, they pressed a stop button
29 resulting in a return to the baseline temperature. For SHPS, subjects verbally rated the pain intensities
30 (same NRS₀₋₁₀ as applied for 8% capsaicin pretreatment) following each heat stimulus. A stimulus went
31 from a 32°C baseline to a 3 seconds plateau at 46°C and with ramping of 5°C/s. Inter-stimuli intervals
32 were 10 seconds. Subjects were unable to observe the probe temperatures during the assessments. For
33 SHPS, short 46°C stimuli were applied to induce mild to moderate pain without evoking discernable,
34 prolonged neurogenic inflammation (evoked around 48°C ⁸⁷), which could interfere with subsequent

1 chemically evoked vasomotor responses. Additionally, the stimulus intensity was chosen considering that
2 it would be tolerable in all subjects and to avoid induction of sensitization. While HPT is thought to be
3 encoded predominantly by mechano-heat-sensitive C-fibers ('CMH', possibly the quickly adapting
4 subtype), the SHPS assessment was conducted to more broadly activate heat-sensitive nociceptors,
5 including CMH, C-mechano-insensitive (CMi), and possibly type-II A δ -fibers^{23,40,50,84,89}. Both HPT and
6 SHPS, were calculated as means of the three consecutive stimuli. Δ HPT and Δ SHPS were defined as the
7 average difference before vs after provocations. For correlation analyses, Δ HPT₂ and Δ SHPS₂ were used,
8 defined as the average difference between vehicle and ablated areas at baseline.

9 **2.4. Application of chemical provocations**

10 After the initial sensory testing, a solution containing either 10% allyl isothiocyanate (hereafter referred to
11 as 'AITC10%') or 1% capsaicin (hereafter referred to as 'CAP1%') was applied to the pretreated areas.
12 The AITC (Sigma Aldrich, Brøndby, Denmark) was dissolved in 99% pharmaceutical grade paraffin
13 (Løve Apoteket, Aalborg, Denmark) at a concentration of 10% AITC (vol/vol). This concentration was
14 determined from previous studies^{49,77}, including a recently published dose-response study¹⁰. Capsaicin
15 was dissolved in a solution of 30% deionized water and 70% ethanol at a concentration of 1% (10mg/mL;
16 Skanderborg Apotek, Denmark). For both AITC10% and CAP1%, a 50 μ l solution was dispensed onto
17 filter disc placed in a 12mm Finn chamber attached with BSN medical tape (Fixomull Stretch, BSN
18 Medical AB, Billdal Sweden). Because AITC penetrates into the epidermis and evokes pain more rapidly
19 than capsaicin, the AITC chamber was left on for 5 minutes while the capsaicin chamber was left on for
20 20 minutes in accordance with previous studies^{49,65}. Following application of provocation compounds,
21 subjects rated the pain intensity on a digital VAS (VAS₀₋₁₀₀; "no pain" = 0 to "worst imaginable pain"=
22 100) for 6 minutes (AITC10%) or 25 minutes (CAP1%). This was done using eVAS software (Aalborg
23 University, Denmark) installed on a 10.1" Samsung tablet computer (Samsung Electronics, Seoul, Korea),
24 and with pain intensity sampled at 0.2 Hz, which allowed for a continuous recording of pain intensity.
25 Chemically evoked pain intensity was regarded as the primary outcome of the study.

26 **2.5. Neurogenic inflammation assessed by superficial blood perfusion**

27 Immediately after removing the Finn chambers, superficial blood perfusion was measured using a Full-
28 Field Laser-speckle Perfusion Imaging instrument (FLPI-1, Moor Instruments Ltd, Axminster, UK).
29 Measurements were performed at a distance of 35 cm between the FLPI-lens and the skin surface.
30 Exposure time was set to 8.3 ms and gain to 160 units. The data were analyzed using MoorFLPI Review
31 V4.0 software (Moor Instruments Ltd, Axminster, UK). Increase in average and peak superficial blood
32 perfusion, within the marked areas, was used as a measure of the primary neurogenic inflammation
33 intensity. The axon-reflex-flare size, evoked by AITC10% and CAP1%, was calculated as the area

1 exhibiting a >50% increase in superficial blood perfusion, compared to the background baseline perfusion
2 (i.e. the individual baseline capillary perfusion in areas unaffected by any skin provocation). The size was
3 quantified in cm² by relative comparison to the known size of the 4x4 cm area, resulting in an estimate of
4 the size of the secondary neurogenic inflammation or “axon-reflex-response”. A line-approach was used
5 to evaluate the spatial characteristics of the neurogenic inflammatory reaction. An 8 cm line, was marked
6 longitudinally, centered through the administration area. Hereafter, superficial perfusion along this line
7 was quantified and averaged in 0.33 cm increments. These methods have been used in a series of previous
8 studies^{7,8,10,64}.

10 2.6. Statistics

11 Data handling and calculation of descriptive statistics were carried out using Microsoft Excel (Microsoft,
12 NM, USA), while statistical comparisons were performed using SPSS 25.0 (IBM NY, USA). Sample size
13 estimation was conducted using the approached outlined for similar crossover designs^{59,64}. All obtained
14 data are presented as arithmetic means ± the standard error of mean (SEM), unless otherwise stated. The
15 collected data were tested for normality by inspecting Q-Q plots and when needed by Shapiro-Wilk
16 normality test. For combined reporting of statistically significant effects, the lowest F-value was reported.
17 Average and peak pain intensities (NRS and VAS-recordings) were calculated and compared. The
18 primary data analyses were conducted using the repeated measures analysis of variance (RM-ANOVA)
19 with the factors: *Pretreatment* (2 levels; 8% capsaicin ablation and vehicle) and *Provocation* (2 levels;
20 AITC10% and CAP1%). For HPT and SHPS, an additional level of *Time* (2 levels; before and after
21 provocation) was added to the RM-ANOVAs. To assure that the randomized order of stimuli performed
22 in session 3 did not constitute a bias, additional RM-ANOVAs were conducted wherein ‘order’ and
23 ‘anatomical location’ were added as between-subjects factors. Moreover, to comparatively assess the
24 achieved inhibition of AITC and capsaicin-evoked pain %-reductions were calculated and compared
25 using Wilcoxon signed rank Test. Z-score changes evoked by the 8% capsaicin pretreatment were
26 calculated allowing for cross-parameter comparisons relative to outcome variability. The formula: $Z =$
27 $[(\mu_{\text{treatment}} - \mu_{\text{baseline}}) / \sigma_{\text{baseline}}]$ was used. For all tests, Bonferroni post hoc test was used to compensate
28 for multiple comparisons. Correlational analyses between selected parameters were performed by
29 Pearson’s coefficient analysis and corrected by the Holm-Sidak method. A P-value ≤0.05 was considered
30 significant. Asterisks for all figures: * P≤0.05, ** P≤0.01 and *** P≤0.001.

1 **3. Results**

2 Nineteen subjects were enrolled and 18 completed the study sessions. One subject was excluded because
3 of premature self-removal of the patches due to intense pain (drop-out). There were no unexpected side
4 effects from applying either AITC or CAP. No significant differences were observed related to arm
5 dominancy for any of the outcomes. It was specifically assessed and confirmed in all subjects that the 8%
6 capsaicin-evoked pain had completely subsided prior to the beginning of session 3 (24 h after the patch
7 removal), which is in line with a previous study using similar ablation technique⁹. The statistical
8 assessment of a potential effect of provocation order, anatomical location, and interference between
9 stimuli revealed no significant results.

10

11 **3.1. Pain evoked by capsaicin-ablation treatment**

12 During the 24 h topical administration of 8% capsaicin patches, mean application pain plateaued at $3.8 \pm$
13 0.5 (NRS₀₋₁₀) for the right forearm and 3.7 ± 0.6 for left the forearm. There were no differences in pain
14 between the right and left forearms ($F_{1,17} = 0.292$, $P=0.596$). Retrospectively rated average and peak pain
15 intensities during 24 h application reached 3.4 ± 0.3 and 5.5 ± 0.5 , respectively (Fig. 2). Subjects were
16 able to correctly localize the active capsaicin patch site from the vehicle patch in 80.6% of the cases, with
17 50% being the 'by chance'. No visible skin reaction or erythema was present when the patches were
18 removed after 24 h application. Hence, unblinding in a subset of participants was based purely on
19 localization of the evoked pain during application. Subjects reported that pain subsided within 0.5-2 hours
20 after removal of the patches.

21

22 **3.2. Pain intensities following chemical provocations**

23 There was a significant effect of *pretreatment*, on both CAP1% and AITC10% mean and peak pain
24 intensities (lowest test F-value ($F_{1,17} = 30.9$, $P<0.001$; mean pain, Fig. 3A and B)). CAP1%-evoked peak
25 pain intensity decreased from 22.7 ± 4.7 (VAS₀₋₁₀₀) in vehicle-treated areas to 2 ± 0.8 in ablated areas, i.e.
26 a $92.9 \pm 2.5\%$ pain reduction. The very limited CAP1%-evoked pain remaining in the ablated skin areas
27 in 6/18 subjects indicate an almost complete defunctionalization of cutaneous capsaicin-receptiveness.
28 For AITC, evoked peak pain decreased from 27.7 ± 5.2 (VAS₀₋₁₀₀) observed in vehicle-treated areas, to
29 5.6 ± 2.4 in ablated areas, i.e. an $86.9\% \pm 5.0\%$ pain reduction (Fig. 3C and D). Similarly, robust
30 reductions in the ablated areas were observed for mean pain intensity (Fig. 3E and F).

31 There was no main effect between type of *provocation* in mean and peak pain (lowest test F-value: $F_{1,17} =$
32 1.8 , $P=0.202$; peak pain), signifying that the CAP1% and AITC10% provocations evoked similar peak
33 and mean pain intensities. Moreover, the *pretreatment x provocation* interaction was insignificant for
34 mean and peak pain (lowest test F-value: $F_{1,17} = 0.1$, $P=0.757$; peak pain) indicating that the pretreatment-

1 evoked desensitization inhibited subsequent CAP and AITC-evoked pain to a similar extent. Even with
2 isolated testing, the ablation-induced pain reductions for AITC10% and CAP1%-exposed areas, were not
3 different ($P=0.508$).

4 5 **3.3. Thermal sensory sensitivity**

6 There was a significant interaction effect in *pretreatment x provocation x time* in heat pain thresholds
7 (HPT) ($F_{1,17}=9.4$, $P=0.007$). Subsequent post hoc testing showed that capsaicin-ablated areas had
8 significantly higher heat pain thresholds (average temperature across all HPT assessments in the
9 pretreated skin areas: $47.9 \pm 0.5^{\circ}\text{C}$), than did vehicle-pretreated areas (average temperature across all
10 HPT assessments in the pretreated skin areas: $40.6 \pm 0.6^{\circ}\text{C}$, $P<0.001$). This was the case both before and
11 after provocations ($P<0.001$), i.e., the 24 h 8% capsaicin-ablation established significant heat hypoalgesia
12 even after the chemical provocations. In vehicle-pretreated areas, provocation with CAP 1% decreased
13 HPT more robustly than AITC 10% ($P<0.001$), while in ablated areas, the HPT values did not differ
14 between provocations ($P=0.8$, Fig. 4A), constituting an anti-hyperalgesic effect.

15
16 A *pretreatment x time* interaction was found for SHPS ($F_{1,17} = 30.4$, $P<0.001$). Post hoc testing showed
17 lower heat pain sensitivity in ablated areas (avg. NRS_{0-10} ; 1.2 ± 0.3) than vehicle-pretreated areas ($4.5 \pm$
18 0.5) both before and after chemical provocations ($P<0.001$), indicating heat hypoalgesia. There was a
19 significant increase in SHPS in vehicle area subsequent to both provocations, signifying development of
20 heat hyperalgesia, which did not occur in ablated areas ($P<0.001$). The 8% capsaicin-ablation induced an
21 average post-provocation decrease in suprathreshold heat pain ratings of $74.9\% \pm 7.9$ for CAP1% and
22 $74.5\% \pm 7.7$ for AITC10% (Fig. 4B), signifying very robust antihyperalgesic effects.

23
24 For ΔHPT , a *pretreatment x provocation* interaction was evident ($F_{1,17}=9.4$, $P=0.007$). The ΔHPT was
25 significantly reduced in vehicle-pretreated ($-5.2 \pm 0.7^{\circ}\text{C}$) compared with the ablated skin ($-1.0 \pm 0.2^{\circ}\text{C}$,
26 $P<0.001$), for both types of provocations (CAP1%: $P<0.001$, AITC 10%: $P=0.043$), with CAP1%
27 prompting a more pronounced HPT drop than AITC10% only in vehicle-treated areas ($P<0.001$, see Fig.
28 4C). In ablated areas, no differences were found for ΔHPT between provocations with CAP1% and
29 AITC10% ($P=0.932$). For ΔSHPS , there was a significant effect of *pretreatment* ($F_{1,17}= 30.4$, $P<0.001$).
30 Ablated areas showed lower changes in ΔSHPS following provocations (0.2 ± 0.2) than did vehicle-
31 pretreated areas (2.3 ± 0.3 , $P<0.001$, Fig. 4D). For ΔSHPS there were no differences between the two
32 types of provocations ($P=0.534$).

33

1 **3.4. Neurogenic inflammatory response**

2 A *pretreatment x provocation* interaction was found for both mean and peak perfusion (lowest test F-
3 value: $F_{1,17}=4.861$, $P=0.042$, mean perfusion). In ablated areas, no significant differences were found
4 between provocations (mean $P=0.435$, peak $P=0.183$), corresponding to almost entirely indiscernible
5 reactions in most subjects (see Fig. 5). In vehicle areas, CAP1% produced a significantly larger increase
6 in both mean and peak perfusion compared to AITC10% (mean $P=0.023$, peak $P=0.021$). For axon-reflex-
7 flare there was a significant effect of *pretreatment* ($F_{1,17} = 141.7$, $P<0.001$). The capsaicin-ablation caused
8 a decrease in flare size from $7.5 \pm 0.7 \text{ cm}^2$ in vehicle-treated areas to $0.5 \pm 0.5 \text{ cm}^2$ in ablated areas for
9 CAP1% and similarly for AITC10% from $8.0 \pm 0.8 \text{ cm}^2$ to $0.5 \pm 0.4 \text{ cm}^2$ ($P<0.001$, see Fig. 6A and B).
10 No significant effect of *provocation* was found on axon-reflex flare size ($F_{1,17} = 0.213$, $P=0.650$)
11 suggesting that the AITC10% and the CAP1% provocations evoked comparable neurogenic inflammatory
12 responses. The line analysis (Fig. 6C) did not reveal any significant differences in the spatial distribution
13 of the neurogenic inflammatory reaction, in neither the vehicle- nor capsaicin-ablated areas. However, a
14 trend towards a more dispersed, but less homotopically intense AITC10%-induced neurogenic flare was
15 evident (smallest $P=0.11$). Similarly, an insignificant trend towards slightly increased in perfusion was
16 observed for AITC10% capsaicin-ablated areas restricted only to the provocation administration area
17 (Fig. 6C).

18 **3.5. Sex-related differences**

19 For peak pain, an interaction effect was found between *pretreatment x provocation x sex* ($F_{1,16} = 4.7$,
20 $P=0.045$). Subsequent post hoc showed that females had significantly higher peak pain scores in vehicle-
21 pretreated areas following CAP1% (34.2 ± 7.3 , VAS_{0-100}) than did males (11.2 ± 2.6 , $P=0.009$). This was
22 not the case for AITC10% ($P=0.350$). For mean perfusion, a *pretreatment x sex* interaction was found
23 ($F_{2,16} = 4.703$, $P=0.046$). Post hoc tests showed that in female subjects, vehicle-pretreated areas exhibited a
24 higher increase in mean perfusion as compared with that of males. This was true both for CAP1%
25 ($P=0.007$) and to a lesser extent for AITC10% induced reactions ($P=0.05$).

26 **3.6. Correlations**

27 A positive correlation was found between 8% capsaicin-ablation evoked pain and CAP1%-evoked pain in
28 vehicle-pretreated skin ($r=0.676$, $P=0.027$, see Table 1). Similarly, both 8% capsaicin-ablation evoked
29 pain and CAP1%-evoked pain correlated strongly with baseline SHPS (lowest: $r=0.702$, $P=0.001$), which
30 was not the case for AITC10%-evoked pain and SHPS ($P=0.29$). No significant correlation was found
31 between mean capsaicin-ablation evoked pain (24 h) and the obtained difference between SHPS in
32 vehicle and ablated areas at baseline (ΔSHPS_2 , $r=0.577$, $P=0.094$). In vehicle areas, a strong positive
33
34

1 correlation was found for neurogenic flare between CAP1% and AITC10% (mean $r=0.756$, $P<0.001$, peak
2 $r=0.704$, $P=0.001$). No correlation was found between heat sensitivity or CAP1% and AITC10%-evoked
3 pain ($r=0.475$, $P=0.282$), suggesting that sensitivity to provocations by CAP1% does not confer sensitivity
4 to AITC10%.

6 **3.7. Z-scores**

7 Fig. 7 provides a comparative overview of the capsaicin-ablation evoked changes when accounting for the
8 natural variability within each variable. When assessing the efficacy of the different sensory and
9 vasomotor responses for CAP1%, the inhibition of heat hyperalgesia (Δ HPT) showed the highest Z-score,
10 indicating that this parameter most robustly detected the ablation responses. Notice that compared to
11 AITC10%, this effect of the ablation was exclusively driven by CAP1%'s more robust elicitation of heat
12 hyperalgesia (as assessed by HPT) in the vehicle-pretreated areas. For AITC10%, changes in mean axon-
13 reflex flare size exhibited the highest Z-score and this parameter was the 2nd most robust for CAP1%.

15 **4. Discussion**

16 High-concentration capsaicin ablation almost completely abolished both AITC- and capsaicin-evoked
17 pain, heat hyperalgesia, and neurogenic inflammation. For both AITC10% (TRPA1 agonist) and CAP1%
18 (TRPV1 agonist) provocations, the pain intensities were similarly reduced by around 90% by the ablation
19 of capsaicin-sensitive nociceptors. Hence, no differences in the desensitization efficacy of the capsaicin-
20 ablation were observed for the two different TRP-provocations, suggesting that TRPA1-nociceptors in
21 human skin are uniformly TRPV1⁺.

23 **4.1. Capsaicin ablation**

24 Topical high-concentration capsaicin causes defunctionalization of capsaicin-sensitive fibers resulting in
25 profound reduction of contact and laser-evoked heat pain sensitivity^{9,35,43,54,61} properties ascribed to the
26 function of superficial TRPV1⁺ nociceptors^{4,21,62}. It is unclear whether nociceptor activation *per se* is a
27 crucial aspect of this desensitization process. Some clinical studies have asserted that the use of local
28 anesthetics do not reduce the efficacy of the capsaicin-ablation^{44,68,83}. Experimental studies have found an
29 association between the pain experienced during patch application and the efficacy of the desensitization
30^{9,57,79}. The present study did not show a positive correlation between capsaicin ablation-induced pain and
31 Δ SHPS₂ (difference between vehicle and ablated areas) although a trend was evident (corrected $P=0.09$)
32 suggesting that the vigorousness of the nociceptive barrage during the ablation and the resultant
33 desensitization are not strictly aligned.

1 **4.2. Capsaicin 8% pre-treatment inhibits both TRPV1 and TRPA1-evoked responses**

2 Previous studies using similar chemical provocation techniques have found pain intensity curves and
3 neurogenic inflammation for both AITC and capsaicin, which were comparable to the present findings
4 ^{10,49,65,77}. Currently, profound reductions in both mean and peak pain were seen in capsaicin-ablated areas
5 when subsequently exposed to AITC10% or CAP1% with no significant differences between the two
6 provocations. This suggests that the defunctionalization of TRPV1-expressing cutaneous fibers robustly
7 abolishes TRPA1-evoked nociceptive responses and implies that no functionally significant
8 subpopulation of nociceptors in human skin are TRPA1⁺/TRPV1⁻. These functional human data support
9 animal studies suggesting that TRPA1 receptors are almost completely co-expressed with TRPV1
10 receptors ^{41,46,81} (see section 4.3). Strong correlations were present between heat pain sensitivity and
11 capsaicin-evoked pain in vehicle-treated area. On the contrary, a complete lack of correlations was
12 observed between AITC-evoked pain versus heat or capsaicin-evoked pain. With our main conclusion in
13 mind, AITC thus produces pain in a distinct manner compared to heat or capsaicin. Since the prolonged
14 capsaicin pretreatment is thought to defunctionalize and ablate fiber branches and this practically
15 abolished AITC-reactivity, it is highly conceivable that AITC-evoked pain is distinct at the receptors level
16 (i.e. engaging TRPA1) while it appears to rely on TRPV1⁺-fibers.

17 Mechanistically, development of primary heat hyperalgesia involves sensitization of both A δ - and C-
18 fibers ⁷⁸ and it is well documented to occur following topical application of capsaicin ⁶¹ and AITC ^{10,77}.
19 Notably, and distinct from e.g. allodynia, primary heat hyperalgesia can be evoked without spontaneous
20 preceding or ongoing pain (e.g. following UVB irradiation) ³⁵. In the present study both short-term topical
21 AITC10% and CAP1% provocations generated substantial heat hyperalgesia in vehicle-pretreated skin.
22 However, following a prolonged high-concentration capsaicin ablation, the development of heat
23 hyperalgesia was entirely abolished and replaced by stable heat hypoalgesia. This signifies that no
24 sensitization of heat-sensitive nociceptors occurred and that no sensitization of a potential heat-insensitive
25 TRPA1⁺/TRPV1⁻ nociceptor subpopulation resulted in *de novo* heat pain receptiveness. In this context, it
26 has been suggested that rodent TRPV1⁻ heat-insensitive nociceptors may develop heat pain sensitivity
27 during partially TRPA1-mediated inflammation ³⁰, but these fibers alone are insufficient for the
28 establishment of heat hyperalgesia ⁴⁷. This notion is corroborated by the present study. It is very likely
29 that TRPA1-mediated heat hyperalgesia is caused by peripheral sensitization of nerve fibers co-
30 expressing TRPV1, although the exact molecular mechanism(s) for such heat sensitization is unclear
31 ^{26,36,86}. Presently, the defunctionalization of such nerves markedly inhibited the effect of AITC. The
32 stronger heat hyperalgesia observed for HPT in vehicle-pretreated skin following CAP1% could signify
33 preferential effect on a subset of heat-sensitive nociceptors, which express TRPV1, but not TRPA1.

1 Based on evidence from primate microneurography it could be speculated that the drastic HPT decreases
2 observed in vehicle-pretreated skin is mediated predominantly by CMH-fibers while a more considerable
3 contribution from additional sensitized heat-nociceptor populations likely contributes to the elevated
4 SHPS^{23,40,50,84,89}. Following ablation, essentially all heat sensitive units (CMH, CMi and A δ -fibers)
5 activated in the TRPV1 activation range would be defunctionalized and thus the heat pain sensitivity
6 diminishes (HPT and SHPS) and no heat hyperalgesia following AITC10% or CAP1% can be mounted.

7 The axon-reflex-flare response is mediated predominantly by CMi-fibers through release of vasoactive
8 peptides⁷³⁻⁷⁵. In vehicle-pretreated skin, AITC10% and CAP1% induced similar neurogenic flare
9 reactions suggesting that the same substrate is engaged by both provocations and that differences in
10 transdermal penetration were reasonably well accounted for. At the receptor-level, AITC has been
11 proposed to induce neurogenic inflammation in a TRPV1-independent manner in rodents¹⁵. However,
12 there are notable differences between neurogenic inflammatory characteristics in human and rodent skin
13⁷⁵. Presently, the 24 h capsaicin ablation resulted in an almost complete inhibition of the axon-reflex-flare,
14 and robustly reduced increases in mean and peak perfusion after chemical provocations. The inhibitory
15 effect of capsaicin-induced defunctionalization on neurogenic flare evoked by various irritants is well
16 established^{25,33,35,55,73}. As the inhibition of the axon-reflex-flare caused by the ablation was similar for
17 both areas treated with CAP1% and AITC10%, the induced flares presumably depend entirely on
18 TRPA1⁺/TRPV1⁺ CMi-fibers neurons. This is corroborated by microneurography studies in humans
19 showing that CMi-units are almost always capsaicin-sensitive^{72,76}. Lastly, considering the different
20 quantification methods, the observed neurogenic inflammatory reactions (7.35 cm²; AITC10% and
21 CAP1% averaged) correspond well with previously reported receptive field sizes for human CMi-fibers
22 assessed by microneurography (range: 1.1–14.2 cm², median; 5.34 cm²)⁷¹.

23

24 **4.3. TRPV1 and TRPA1 co-expression**

25 Story *et al.* (2003) found TRPA1 mRNA expressed in all TRPV1⁺ rodent DRG neurons⁸¹. Likewise,
26 when functionally assessed, TRPA1⁺ rat trigeminal neurons were shown to be TRPV1⁺ too, i.e.,
27 responding to AITC as well as capsaicin⁴¹. Similar findings have been reported in several studies^{18,46}.
28 Contrasting these initial studies, Malin *et al.* (2011) demonstrated that skin afferents express TRPV1,
29 TRPA1 or both more rarely than previously assumed, i.e., 22% expressed TRPV1 mRNA, 6% expressed
30 TRPA1, but only 10% expressed both TRPV1 and TRPA1⁵⁶. Another study on mice DRG-neurons
31 showed that 49.7% of units solely expressed TRPV1, 43% TRPA1, but only 99 of 149 TRPA1⁺-neurons
32 co-expressed TRPV1⁸² which is aligned approximately with recent results from rat trigeminal neurons³⁷.
33 Finally, RNA-sequencing in mice DRG-neurons have shown a subpopulation of nociceptors expressing

1 TRPA1 and MrgprD, but not TRPV1^{85,90}. Distinct innervation of various tissues and differences in DRG
2 and axonal mRNA expression may, in part, explain the contradictory findings^{24,56}. The present study used
3 a capsaicin-ablation intervention to estimate the functional co-expression of TRPA1 and TRPV1 in
4 human epidermal nerve fibers and findings support the notion of TRPA1 being expressed in a subset of
5 TRPV1⁺ fibers as described in early rodent studies. In this context, it should be highlighted that
6 substantial interspecies differences are well documented within somatosensory afferent neurophysiology
7 and transducer expression^{29,52}. This study adds information about the interdependency of TRPA1 and
8 TRPV1-evoked responses in humans, where prior evidence is scarce. *in vitro* responses of sensory
9 neurons indicate transient homologous and heterologous desensitization mechanisms for TRPA1 and
10 TRPV1 when stimulated with AITC and capsaicin¹, while some *in vivo* data contradict this notion¹⁵.
11 Data by Simons *et al.* (2003) using administration to the oral mucosa of capsaicin and AITC in humans,
12 also suggested rapid self- and cross-desensitization between the two agonists⁸⁰. However, AITC-evoked
13 responses following a prolonged capsaicin-induced desensitization have not previously been studied in
14 humans and TRPA1-agonists do not appear to induce desensitization in human skin. The discrepancies
15 between data from oral mucosa and skin probably are related to different study designs, including diverse
16 concentrations and exposure times, as well as tissue-related differences in e.g. sensory sensitivity,
17 penetration, and clearance (all of which are remarkably higher in the oral mucosa compared to the skin).
18 Notably, many of the pain and itch conditions where TRPA1 and TRPV1 antagonists have been proposed
19 to be of potential clinical utility, involve skin targeting (e.g. inflammatory skin diseases and peripheral
20 neuropathies^{12,30,34,48}).

21

22 **4.4. Clinical implications**

23 Development of systemic and topical antagonists for TRPA1 and TRPV1 is currently ongoing and several
24 lead compounds have been, and are being, tested in clinical trials^{42,58,66}. The efficacy of selective TRP-
25 antagonists have unfortunately so far not shown strong clinical effects in chronic pain and, e.g., TRPV1
26 antagonists have shown considerable adverse effects such as hyperthermia⁵⁸. To achieve better efficacy
27 developing dual TRP-antagonists (e.g. targeting both TRPV1 and TRPA1) might be an option to increase
28 the therapeutic window. Just as selective activation of TRPV1 and TRPA1 is performed in animal drug
29 profiling studies, it is possible to test, e.g. TRPV1-antagonists for effect and target engagement in early
30 clinical drug trials^{13,34} but this requires reliable provocation models. The profound responsiveness
31 observed for FLPI-measured neurogenic inflammation supports monitoring this outcome in response to
32 TRPA1 or TRPV1 agonist provocation as a suitable and sensitive target engagement biomarker in
33 humans^{13,20,34}. Chemical activation of TRPV1 and TRPA1 may also be used for sensory profiling
34 purposes in patients with, e.g., peripheral neuropathic pain conditions and adds to the existing QST

1 platforms as a way to translate pre-clinical findings into patients ¹⁶. Such receptor profiling may provide
2 additional information on loss- or gain-of-function for these specific receptor populations and similar
3 mechanistic phenotyping has been shown to predict the effect of certain analgesics ²⁷. The current
4 receptor-specific provocation models may also be used for testing, e.g., novel TRPA1-antagonists and
5 recently clinical studies have been initiated provoking TRPA1/TRPV1-responses in patients with, for
6 instance allergies or inflammatory dermatoses, to investigate itch, pain and inflammatory responses ^{2,5,6,39}.

8 **4.5. Limitations and future perspectives**

9 While topical high-concentration capsaicin could potentially evoke effects on non-neuronal tissues, such
10 as endothelial cells or unspecifically desensitize nerve terminals independently of TRPV1, for instance
11 through mitochondrial respiratory distress or off-target effects related to the induced inflammation, such
12 effects are probably marginal. TRPA1-modulation by inflammation generally appears to enhance TRPA1-
13 expression and function ^{31,38,60}, while capsaicin-induced ablation is thought to rely on Ca²⁺-influx overload
14 through TRPV1 as well as mismatch between high energy expenditure (given the prolonged vigorous
15 firing induced by TRPV1-activation coupled with dysfunctional mitochondrial metabolism) ^{4,62}. This
16 relative TRPV1-specificity of the applied ablation, is supported by the fact that no lingering inflammation
17 is present when 8% capsaicin patches are removed, and the endothelial reactivity assessed by wheal
18 responsiveness (an entirely non-neurogenic reflex) is normal in ablated skin ⁹. Moreover, psychophysical
19 evidence suggests that only warmth and heat sensitivity are very robustly decreased in skin following 8%
20 capsaicin pretreatment ^{35,54}. The fact that unblinding occurred in a subset of subjects, has limited impact
21 both because testing occurred 24 h after identification (which was never revealed to the subject) but also
22 because the primary analyses simply compared the achieved relative inhibition for the two chemical
23 provocations. A key premise was TRPV1 and TRPA1 activation by capsaicin and AITC, respectively.
24 The selectivity of the two TRP-agonists, AITC in particular, has been questioned ^{3,32,56}, but overall a large
25 amount of evidence support their relative specificity ^{11,14,17,41,53,71}. More importantly in this context, even if
26 a proportion of the nociceptive response of AITC was mediated by direct TRPV1-activation, the basic
27 result interpretation would have remained unchanged. Similarly, even if prolonged capsaicin exposure
28 causes heterologous desensitization of TRPA1-channels that would still only apply to fibers expressing
29 TRPV1 and would thus leave a potential population of TRPV1⁻ and TRPA1⁺-fibers unaffected. Because a
30 robust correlation was present between SHPS or HPT and CAP1%-induced pain but not AITC10% pain,
31 such unspecific AITC-engagement of TRPV1 seems unlikely. Lastly, the present study did not assess to
32 which extent capsaicin-sensitivity is maintained following a TRPA1-associated nerve fiber
33 defunctionalization and thus cannot evaluate the significance and function of TRPV1⁺, but TRPA1⁻
34 cutaneous nociceptors. Such a subpopulation is uniformly reported in rodents and thus likely exists in

1 human skin^{46,85}. Unfortunately, a parallel method for TRPA1-associated defunctionalization in human
2 skin does not yet exist and prolonged topical application of TRPA1-agonists is generally associated with
3 more prolonged and extensive skin inflammation than TRPV1-agonists¹⁰.

4 5 **5. Conclusion**

6 Ablation of capsaicin-sensitive cutaneous fibers using high-concentration capsaicin strongly inhibited
7 both AITC and capsaicin-evoked responses, including spontaneous pain, heat hyperalgesia, and
8 neurogenic inflammation. The inhibition was consistent across all parameters and of similar
9 efficaciousness for both chemical provocations. Thus, normal nociceptive AITC-responses are robustly
10 inhibited when capsaicin-sensitive cutaneous nerve fibers are defunctionalized. This suggests that in
11 human skin, TRPA1⁺ primary cutaneous afferents belong to a subpopulation of TRPV1⁺ nociceptors.

12 13 **6. Acknowledgements**

14 HHA acknowledges support from the EliteForsk Travel Stipend (2016) awarded by the Danish Ministry
15 of Science and Higher Education as well as the Spar Nord Foundation's Research Award 2018. This
16 study was supported by SMI and the Clinical Institute, Aalborg University, Denmark.

17 18 **7. References**

- 19
20 [1] Akopian AN, Ruparel NB, Jeske NA, Hargreaves KM. Transient receptor potential TRPA1 channel
21 desensitization in sensory neurons is agonist dependent and regulated by TRPV1-directed internalization. *J*
22 *Physiol* 2007;583:175–93.
- 23 [2] Alenmyr L, Hogestatt ED, Zygmunt PM, Greiff L. TRPV1-mediated itch in seasonal allergic rhinitis.
24 *Allergy* 2009;64:807–10. doi:10.1111/j.1398-9995.2009.01937.x.
- 25 [3] Alpizar YA, Boonen B, Gees M, Sanchez A, Nilius B, Voets T, Talavera K. Allyl isothiocyanate sensitizes
26 TRPV1 to heat stimulation. *Pflugers Arch Eur J Physiol* 2014;466:507–15.
- 27 [4] Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of
28 the new high-concentration capsaicin 8% patch. *Br J Anaesth* 2011;107:490–502. doi:10.1093/bja/aer260.
- 29 [5] Andersen HH, Akiyama T, Nattkemper LA, van Laarhoven A, Elberling J, Yosipovitch G, Arendt-Nielsen
30 L. Allodynia and hyperknesis - mechanisms, assessment methodology and clinical implications of itch
31 sensitization. *Pain* 2018;1. doi:10.1097/j.pain.0000000000001220.
- 32 [6] Andersen HH, Elberling J, Sharma N, Hauberg LE, Gazerani P, Arendt-Nielsen L. Histaminergic and non-
33 histaminergic elicited itch is attenuated in capsaicin-evoked areas of allodynia and hyperalgesia: A healthy
34 volunteer study. *Eur J Pain* 2017;21:1098–109. doi:10.1002/ejp.1013.
- 35 [7] Andersen HH, Elberling J, Lo Vecchio S, Arendt-Nielsen L. Topography of itch. *Itch* 2017;2.
- 36 [8] Andersen HH, Gazerani P, Arendt-Nielsen L. High-Concentration L-Menthol Exhibits Counter-Irritancy to

- 1 Neurogenic Inflammation, Thermal and Mechanical Hyperalgesia Caused by Trans-cinnamaldehyde. *J Pain*
2 2016;17:919–29. doi:10.1016/j.jpain.2016.05.004.
- 3 [9] Andersen HH, Marker JB, Hoeck EA, Elberling J, Arendt-Nielsen L. Antipruritic effect of pretreatment with
4 topical capsaicin 8% on histamine- and cowhage-evoked itch in healthy volunteers: a randomized, vehicle-
5 controlled, proof-of-concept trial. *Br J Dermatol* 2017;177:107–16. doi:10.1111/bjd.15335.
- 6 [10] Andersen HH, Lo Vecchio S, Gazerani P, Arendt-Nielsen L. Dose-response study of topical allyl
7 isothiocyanate (mustard oil) as a human surrogate model of pain, hyperalgesia, and neurogenic
8 inflammation. *Pain* 2017;158:1723–32. doi:10.1097/j.pain.0000000000000979.
- 9 [11] Andrade EL, Luiz AP, Ferreira J, Calixto JB. Pronociceptive response elicited by TRPA1 receptor activation
10 in mice. *Neuroscience* 2008;152:511–20. doi:10.1016/j.neuroscience.2007.12.039.
- 11 [12] Andrade EL, Meotti FC, Calixto JB. TRPA1 antagonists as potential analgesic drugs. *Pharmacol Ther*
12 2012;133:189–204. doi:10.1016/j.pharmthera.2011.10.008.
- 13 [13] Arendt-Nielsen L, Harris S, Whiteside GT, Hummel M, Knappenberger T, O'Keefe S, Kapil R, Kyle D. A
14 randomized, double-blind, positive-controlled, 3-way cross-over human experimental pain study of a
15 TRPV1 antagonist (V116517) in healthy volunteers and comparison with preclinical profile. *Pain*
16 2016;157:2057–67.
- 17 [14] Bandell M, Story GM, Hwang SW, Viswanath V, Eid SR, Petrus MJ, Earley TJ, Patapoutian A. Noxious
18 cold ion channel TRPA1 is activated by pungent compounds and bradykinin. *Neuron* 2004;41:849–57.
19 Available: <http://www.ncbi.nlm.nih.gov/pubmed/15046718>.
- 20 [15] Bánvölgyi Á, Pozsgai G, Brain SD, Helyes ZS, Szolcsányi J, Ghosh M, Meleg B, Pintér E. Mustard oil
21 induces a transient receptor potential vanilloid 1 receptor-independent neurogenic inflammation and a non-
22 neurogenic cellular inflammatory component in mice. *Neuroscience* 2004;125:449–59.
- 23 [16] Baron R, Dickenson AH. Neuropathic pain: Precise sensory profiling improves treatment and calls for back-
24 translation. *Pain* 2014;155:2215–7.
- 25 [17] Bautista DM, Jordt SE, Nikai T, Tsuruda PR, Read AJ, Poblete J, Yamoah EN, Basbaum AI, Julius D.
26 TRPA1 Mediates the Inflammatory Actions of Environmental Irritants and Proalgesic Agents. *Cell*
27 2006;124:1269–82.
- 28 [18] Bautista DM, Movahed P, Hinman A, Axelsson HE, Sterner O, Högestätt ED, Julius D, Jordt S, Zygmunt
29 PM. Pungent products from garlic activate the sensory ion channel TRPA1. 2005;102:11248–2252.
- 30 [19] Bautista DM, Pellegrino M, Tsunozaki M. TRPA1: A Gatekeeper for Inflammation. *Annu Rev Physiol*
31 2013;75:181–200. doi:10.1146/annurev-physiol-030212-183811.
- 32 [20] Buntinx L, Chang L, Amin A, Morlion B, de Hoon J. Development of an in vivo target-engagement
33 biomarker for TRPA1 antagonists in humans. *Br J Clin Pharmacol* 2017;83:603–11.
- 34 [21] Cavanaugh DJ, Lee H, Lo L, Shields SD, Zylka MJ, Basbaum AI, Anderson DJ. Distinct subsets of
35 unmyelinated primary sensory fibers mediate behavioral responses to noxious thermal and mechanical
36 stimuli. *Proc Natl Acad Sci* 2009;106:9075–80. doi:10.1073/pnas.0901507106.
- 37 [22] Chen J, Zhang X-F, Kort ME, Huth JR, Sun C, Miesbauer LJ, Cassar SC, Neelands T, Scott VE, Moreland

- 1 RB, Reilly RM, Hajduk PJ, Kym PR, Hutchins CW, Faltynek CR. Molecular determinants of species-
2 specific activation or blockade of TRPA1 channels. *J Neurosci* 2008;28:5063–71.
- 3 [23] Churyukanov M, Plaghki L, Legrain V, Mouraux A. Thermal detection thresholds of A δ - and C-fibre
4 afferents activated by brief CO₂ laser pulses applied onto the human hairy skin. *PLoS One* 2012;7:e35817.
5 doi:10.1371/journal.pone.0035817.
- 6 [24] Costa CJ, Willis DE. To the end of the line: Axonal mRNA transport and local translation in health and
7 neurodegenerative disease. *Dev Neurobiol* 2017. doi:10.1002/dneu.22555.
- 8 [25] Crimi N, Polosa R, Maccarrone C, Palermo B, Palermo F, Mistretta A. Effect of topical administration with
9 capsaicin on skin responses to bradykinin and histamine in man. *Clin Exp Allergy* 1992;22:933–9.
- 10 [26] Davis JB, Gray J, Gunthorpe MJ, Hatcher JP, Davey PT, Overend P, Harries MH, Latcham J, Clapham C,
11 Atkinson K, Hughes SA, Rance K, Grau E, Harper AJ, Pugh PL, Rogers DC, Bingham S, Randall A,
12 Sheardown SA. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. *Nature*
13 2000;405:183–7. doi:10.1038/35012076.
- 14 [27] Demant DT, Lund K, Finnerup NB, Vollert J, Maier C, Segerdahl S, Jensen TS. Pain relief with lidocaine
15 5% patch in localized peripheral neuropathic pain in relation to pain phenotype: a randomised, double-blind,
16 and placebo-controlled, phenotype panel study. 2015;156:2234–44.
- 17 [28] Demartini C, Tassorelli C, Zanaboni AM, Tonsi G, Francesconi O, Nativi C, Greco R. The role of the
18 transient receptor potential ankyrin type-1 (TRPA1) channel in migraine pain: evaluation in an animal
19 model. *J Headache Pain* 2017;18:94.
- 20 [29] Dubin AE, Patapoutian A. Nociceptors: the sensors of the pain pathway. 2010;120.
- 21 [30] Eid SR, Crown ED, Moore EL, Liang HA, Choong K-C, Dima S, Henze DA, Kane SA, Urban MO. HC-
22 030031, a TRPA1 Selective Antagonist, Attenuates Inflammatory- and Neuropathy-Induced Mechanical
23 Hypersensitivity. *Mol Pain* 2008;4:1744-8069-4–48. doi:10.1186/1744-8069-4-48.
- 24 [31] Eid SR, Crown ED, Moore EL, Liang HA, Choong KC, Dima S, Henze DA, Kane SA, Urban MO. HC-
25 030031, a TRPA1 selective antagonist, attenuates inflammatory- and neuropathy-induced mechanical
26 hypersensitivity. *Mol Pain* 2008;4:1–10.
- 27 [32] Everaerts W, Gees M, Alpizar YA, Farre R, Leten C, Apetrei A, Dewachter I, Van Leuven F, Vennekens R,
28 De Ridder D, Nilius B, Voets T, Talavera K. The capsaicin receptor TRPV1 is a crucial mediator of the
29 noxious effects of mustard oil. *Curr Biol* 2011;21:316–21. doi:10.1016/j.cub.2011.01.031.
- 30 [33] Geber C, Fondel R, Krämer HH, Rolke R, Treede R-D, Sommer C, Birklein F. Psychophysics, Flare, and
31 Neurosecretory Function in Human Pain Models: Capsaicin Versus Electrically Evoked Pain. *J Pain*
32 2007;8:503–14. doi:10.1016/j.jpain.2007.01.008.
- 33 [34] Gibson R a., Robertson J, Mistry H, McCallum S, Fernando D, Wyres M, Yosipovitch G. A Randomised
34 Trial Evaluating the Effects of the TRPV1 Antagonist SB705498 on Pruritus Induced by Histamine, and
35 Cowhage Challenge in Healthy Volunteers. *PLoS One* 2014;9:e100610. doi:10.1371/journal.pone.0100610.
- 36 [35] Henrich F, Magerl W, Klein T, Greffrath W, Treede R-D. Capsaicin-sensitive C- and A-fibre nociceptors
37 control long-term potentiation-like pain amplification in humans. *Brain* 2015;138:2505–20.

- 1 doi:10.1093/brain/awv108.
- 2 [36] Hoffmann T, Kistner K, Miermeister F, Winkelmann R, Wittmann J, Fischer MJM, Weidner C, Reeh PW.
3 TRPA1 and TRPV1 are differentially involved in heat nociception of mice. *Eur J Pain (United Kingdom)*
4 2013;17:1472–82.
- 5 [37] Honda K, Shinoda M, Furukawa A, Kita K, Noma N, Iwata K. TRPA1 contributes to capsaicin-induced
6 facial cold hyperalgesia in rats. *Eur J Oral Sci* 2014;122:391–6.
- 7 [38] Horváth Á, Tékus V, Boros M, Pozsgai G, Botz B, Borbély É, Szolcsányi J, Pintér E, Helyes Z. Transient
8 receptor potential ankyrin 1 (TRPA1) receptor is involved in chronic arthritis: in vivo study using TRPA1-
9 deficient mice. *Arthritis Res Ther* 2016;18:6. doi:10.1186/s13075-015-0904-y.
- 10 [39] Hosogi M, Schmelz M, Miyachi Y, Ikoma A. Bradykinin is a potent pruritogen in atopic dermatitis: a switch
11 from pain to itch. *Pain* 2006;126:16–23. doi:10.1016/j.pain.2006.06.003.
- 12 [40] Johaneck LM, Meyer RA, Friedman RM, Greenquist KW, Shim B, Borzan J, Hartke T, LaMotte RH,
13 Ringkamp M. A Role for Polymodal C-Fiber Afferents in Nonhistaminergic Itch. *J Neurosci* 2008;28:7659–
14 69. doi:10.1523/JNEUROSCI.1760-08.2008.
- 15 [41] Jordt S-E, Bautista DM, Chuang H, McKemy DD, Zygmunt PM, Högestätt ED, Meng ID, Julius D. Mustard
16 oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1. *Nature*
17 2004;427:260–5. doi:10.1038/nature02282.
- 18 [42] Kaneko Y, Szallasi A. Transient receptor potential (TRP) channels: A clinical perspective. *Br J Pharmacol*
19 2014;171:2474–507.
- 20 [43] Kennedy WR, Vanhove GF, Lu S ping, Tobias J, Bley KR, Walk D, Wendelschafer-Crabb G, Simone DA,
21 Selim MM. A Randomized, Controlled, Open-Label Study of the Long-Term Effects of NGX-4010, a High-
22 Concentration Capsaicin Patch, on Epidermal Nerve Fiber Density and Sensory Function in Healthy
23 Volunteers. *J Pain* 2010;11:579–87.
- 24 [44] Kern K, Nowack W, Poole C. Treatment of Neuropathic Pain with the Capsaicin 8 % Patch : Is Pretreatment
25 with Lidocaine Necessary ? 2014;14:42–50.
- 26 [45] Kittaka H, Tominaga M. The molecular and cellular mechanisms of itch and the involvement of TRP
27 channels in the peripheral sensory nervous system and skin. *Allergol Int* 2016:1–9.
28 doi:10.1016/j.alit.2016.10.003.
- 29 [46] Kobayashi K, Fukuoka T, Obata K, Yamanaka H, Dai Y, Tokunaga A, Noguchi K. Distinct expression of
30 TRPM8, TRPA1, and TRPV1 mRNAs in rat primary afferent neurons with A δ /C-fibers and colocalization
31 with Trk receptors. *J Comp Neurol* 2005;493:596–606.
- 32 [47] Koerber HR, McIlwrath SL, Lawson JJ, Malin SA, Anderson CE, Jankowski MP, Davis BM. Cutaneous C-
33 polymodal fibers lacking TRPV1 are sensitized to heat following inflammation, but fail to drive heat
34 hyperalgesia in the absence of TPV1 containing C-heat fibers. *Mol Pain* 2010;6:1–11.
- 35 [48] Koivisto A, Hukkanen M, Saarnilehto M, Chapman H, Kuokkanen K, Wei H, Viisanen H, Åkerman KE,
36 Lindstedt K, Pertovaara A. Inhibiting TRPA1 ion channel reduces loss of cutaneous nerve fiber function in
37 diabetic animals: Sustained activation of the TRPA1 channel contributes to the pathogenesis of peripheral

- 1 diabetic neuropathy. *Pharmacol Res* 2012;65:149–58. doi:10.1016/j.phrs.2011.10.006.
- 2 [49] Koltzenburg M, Lundberg LE, Torebjörk HE. Dynamic and static components of mechanical hyperalgesia in
3 human hairy skin. *Pain* 1992;51:207–19.
- 4 [50] LaMotte RH, Thalhammer JG, Robinson CJ. Peripheral Neural Correlates of Magnitude of Cutaneous Pain
5 and Hyperalgesia : a Comparison of Neural Events in Monkey With Sensory Judgments in Human.
6 *Neurophysiology* 1983;50:1–26.
- 7 [51] Lieu T, Jayaweera G, Zhao P, Poole DP, Jensen D, Grace M, McIntyre P, Bron R, Wilson YM, Krappitz M,
8 Haerteis S, Korbmacher C, Steinhoff MS, Nassini R, Materazzi S, Geppetti P, Corvera CU, Bunnett NW.
9 The bile acid receptor TGR5 activates the trpa1 channel to induce itch in mice. *Gastroenterology*
10 2014;147:1417–28. doi:10.1053/j.gastro.2014.08.042.
- 11 [52] Ma C, Nie H, Gu Q, Sikand P, Lamotte RH. In vivo responses of cutaneous C-mechanosensitive neurons in
12 mouse to punctate chemical stimuli that elicit itch and nociceptive sensations in humans. *J Neurophysiol*
13 2012;107:357–63. doi:10.1152/jn.00801.2011.
- 14 [53] Macpherson LJ, Dubin AE, Evans MJ, Marr F, Schultz PG, Cravatt BF, Patapoutian A. Noxious compounds
15 activate TRPA1 ion channels through covalent modification of cysteines. *Nature* 2007;445:541–5.
- 16 [54] Magerl W, Fuchs PN, Meyer RA, Treede RD. Roles of capsaicin-insensitive nociceptors in cutaneous pain
17 and secondary hyperalgesia. *Brain* 2001;124:1754–64. doi:10.1093/brain/124.9.1754.
- 18 [55] Magerl W, Szolcsányi J, Westerman RA, Handwerker HO. Laser Doppler measurements of skin
19 vasodilation elicited by percutaneous electrical stimulation of nociceptors in humans. *Neurosci Lett*
20 1987;82:349–54.
- 21 [56] Malin S, Molliver D, Christianson JA, Schwartz ES, Cornuet P, Albers KM, Davis BM. TRPV1 and TRPA1
22 Function and Modulation Are Target Tissue Dependent. *J Neurosci* 2011;31:10516–28.
- 23 [57] Malmberg AB, Mizisin AP, Calcutt NA, von Stein T, Robbins WR, Bley KR. Reduced heat sensitivity and
24 epidermal nerve fiber immunostaining following single applications of a high-concentration capsaicin patch.
25 *Pain* 2004;111:360–7. doi:10.1016/j.pain.2004.07.017.
- 26 [58] Moran MM, Szallasi A. Targeting nociceptive TRP channels to treat chronic pain: current state of the field.
27 *Br J Pharmacol* 2017:1–19.
- 28 [59] Mørch CD, Gazerani P, Nielsen TA, Arendt-Nielsen L. The UVB cutaneous inflammatory pain model: A
29 reproducibility study in healthy volunteers. *Int J Physiol Pathophysiol Pharmacol* 2013;5:203–15.
- 30 [60] Nattkemper LA, Tey HL, Valdes-Rodriguez R, Lee H, Mollanazar NK, Albornoz C, Sanders KM,
31 Yosipovitch G. The Genetics of Chronic Itch: Gene Expression in the Skin of Patients with Atopic
32 Dermatitis and Psoriasis with Severe Itch. *J Invest Dermatol* 2018. doi:10.1016/j.jid.2017.12.029.
- 33 [61] Nolano M, Simone DA, Wendelschafer-Crabb G, Johnson T, Hazen E, Kennedy WR. Topical capsaicin in
34 humans: Parallel loss of epidermal nerve fibers and pain sensation. *Pain* 1999;81:135–45.
- 35 [62] O’Neill J, Brock C, Olesen AE, Andresen T, Nilsson M, Dickenson AH. Unravelling the mystery of
36 capsaicin: a tool to understand and treat pain. *Pharmacol Rev* 2012;64:939–71. doi:10.1124/pr.112.006163.
- 37 [63] Oh M-HM-H, Oh SY, Lu J, Lou H, Myers AC, Zhu Z, Zheng T. TRPA1-dependent pruritus in IL-13-

- 1 induced chronic atopic dermatitis. *J Immunol* 2013;191:5371–82. doi:10.4049/jimmunol.1300300.
- 2 [64] Olsen RV, Andersen HH, Møller HG, Eskelund PW, Arendt-Nielsen L. Somatosensory and vasomotor
3 manifestations of individual and combined stimulation of TRPM8 and TRPA1 using topical L-menthol and
4 trans-cinnamaldehyde in healthy volunteers. *Eur J Pain (United Kingdom)* 2014;18.
- 5 [65] Petersen LJ, Lyngholm AM, Arendt-Nielsen L. A novel model of inflammatory pain in human skin
6 involving topical application of sodium lauryl sulfate. *Inflamm Res* 2010;59:775–81. doi:10.1007/s00011-
7 010-0189-1.
- 8 [66] Preti D, Saponaro G, Szallasi A. Transient receptor potential ankyrin 1 (TRPA1) antagonists. *Pharm Pat*
9 *Anal* 2015;4:75–94. doi:10.4155/ppa.14.60.
- 10 [67] R. Garrison S, L. Stucky C. The Dynamic TRPA1 Channel: A Suitable Pharmacological Pain Target? *Curr*
11 *Pharm Biotechnol* 2011;12:1689–97.
- 12 [68] Raber JM, Reichelt D, Grüneberg-Oelker U, Philipp K, Stubbe-Dräger B, Husstedt I-W. Capsaicin 8 % as a
13 cutaneous patch (QutenzaTM): analgesic effect on patients with peripheral neuropathic pain. *Acta Neurol*
14 *Belg* 2014. doi:10.1007/s13760-014-0395-7.
- 15 [69] Rolke R, Baron R, Maier C, Tölle TR, Treede - D. R., Beyer A, Binder A, Birbaumer N, Birklein F, Bötefür
16 IC, Braune S, Flor H, Hüge V, Klug R, Landwehrmeyer GB, Magerl W, Maihöfner C, Rolko C, Schaub C,
17 Scherens A, Sprenger T, Valet M, Wasserka B. Quantitative sensory testing in the German Research
18 Network on Neuropathic Pain (DFNS): Standardized protocol and reference values. *Pain* 2006;123:231–43.
19 doi:10.1016/j.pain.2006.01.041.
- 20 [70] Rolke R, Magerl W, Campbell KA, Schalber C, Caspari S, Birklein F, Treede R-D. Quantitative sensory
21 testing: a comprehensive protocol for clinical trials. *Eur J Pain* 2006;10:77–88.
- 22 [71] Sawyer CM, Carstens MI, Carstens E. Mustard oil enhances spinal neuronal responses to noxious heat but
23 not cooling. *Neurosci Lett* 2009;461:271–4.
- 24 [72] Schmelz M. Chemical Response Pattern of Different Classes of C-Nociceptors to Pruritogens and Algogens.
25 *J Neurophysiol* 2003;89:2441–8. doi:10.1152/jn.01139.2002.
- 26 [73] Schmelz M, Luz O, Averbek B, Bickel a. Plasma extravasation and neuropeptide release in human skin as
27 measured by intradermal microdialysis. *Neurosci Lett* 1997;230:117–20.
- 28 [74] Schmelz M, Michael K, Weidner C, Torebjörk H, Handwerker H. Which nerve fibers mediate the axon
29 reflex flare in human skin? *Neuroreport* 2000;11:645–8. Available:
30 http://journals.lww.com/neuroreport/Abstract/2000/02280/Which_nerve_fibers_mediate_the_axon_reflex_flare.41.aspx. Accessed 13 May 2013.
- 31
- 32 [75] Schmelz M, Petersen LJ. Neurogenic inflammation in human and rodent skin. *Physiology* 2001;16:33–7.
- 33 [76] Schmelz M, Schmid R, Handwerker HO, Torebjörk HE. Encoding of burning pain from capsaicin-treated
34 human skin in two categories of unmyelinated nerve fibres. *Brain* 2000;123:560–71.
35 doi:10.1093/brain/123.3.560.
- 36 [77] Schmelz M, Schmidt R, Ringkamp M, Forster C, Handwerker HO, Torebjörk HE. Limitation of
37 sensitization to injured parts of receptive fields in human skin C-nociceptors. *Exp brain Res* 1996;109:141–

- 1 7. Available: <http://www.ncbi.nlm.nih.gov/pubmed/8740217>.
- 2 [78] Schmidt RF, Willis WD. *Encyclopedia of Pain*. 2015 p.
- 3 [79] Simone DA, Nolano M, Johnson T, Wendelschafer-Crabb G, Kennedy WR. Intradermal injection of
4 capsaicin in humans produces degeneration and subsequent reinnervation of epidermal nerve fibers:
5 correlation with sensory function. *J Neurosci* 1998;18:8947–59.
- 6 [80] Simons CT, Carstens MI, Carstens E. Oral irritation by mustard oil: Self-desensitization and cross-
7 desensitization with capsaicin. *Chem Senses* 2003;28:459–65.
- 8 [81] Story GM, Peier AM, Reeve AJ, Eid SR, Mosbacher J, Hricik TR, Earley TJ, Hergarden AC, Andersson
9 DA, Hwang SW, McIntyre P, Jegla T, Bevan S, Patapoutian A. ANKTM1, a TRP-like channel expressed in
10 nociceptive neurons, is activated by cold temperatures. *Cell* 2003;112:819–29. Available:
11 <http://www.ncbi.nlm.nih.gov/pubmed/12654248>.
- 12 [82] Than JY-XLXL, Li L, Hasan R, Zhang X. Excitation and Modulation of TRPA1, TRPV1, and TRPM8
13 Channel-expressing Sensory Neurons by the Pruritogen Chloroquine. *J Biol Chem* 2013;288:12818–27.
14 doi:10.1074/jbc.M113.450072.
- 15 [83] Treede R-D, Wagner T, Kern K-U, Husstedt I., Arendt G, Bircklein F, Cegla T, Freynhagen R, Gockel H,
16 Heskamp M, Jager H, Joppich R, Maier C, Leffler A, Nagelein H, Rolke R, Seddigh S, Sommer C, Stander
17 S, Wasner G, Baron R. Mechanism- and experience-based strategies to optimize treatment response to the
18 capsaicin 8 % cutaneous patch in patients with localized neuropathic pain. 2013;29:527–38.
- 19 [84] Treede RD, Meyer RA, Raja SN, Campbell JN. Evidence for two different heat transduction mechanisms in
20 nociceptive primary afferents innervating monkey skin. *J Physiol* 1995;483 (Pt 3):747–58. Available:
21 <http://www.ncbi.nlm.nih.gov/pubmed/7776255>.
- 22 [85] Usoskin D, Furlan A, Islam S, Abdo H, Lönnerberg P, Lou D, Hjerling-Leffler J, Haeggström J,
23 Kharchenko O, Kharchenko P V., Linnarsson S, Ernfors P. Unbiased classification of sensory neuron types
24 by large-scale single-cell RNA sequencing. *Nat Neurosci* 2015;18:145–53. doi:10.1038/nn.3881.
- 25 [86] Vandewauw I, De Clercq K, Mulier M, Held K, Pinto S, Van Ranst N, Segal A, Voet T, Vennekens R,
26 Zimmermann K, Vriens J, Voets T. A TRP channel trio mediates acute noxious heat sensing. *Nature*
27 2018;555:662–6. doi:10.1038/nature26137.
- 28 [87] Weidner C, Schmelz M, Schmidt R, Hansson B, Handwerker HO, Torebjörk HE. Functional attributes
29 discriminating mechano-insensitive and mechano-responsive C nociceptors in human skin. *J Neurosci*
30 1999;19:10184–90.
- 31 [88] Wilson SR, Gerhold KA, Bifulco-Fisher A, Liu Q, Patel KN, Dong X, Bautista DM. TRPA1 is required for
32 histamine-independent, Mas-related G protein-coupled receptor-mediated itch. *Nat Neurosci* 2011;14:595–
33 602.
- 34 [89] Wooten M, Weng H-J, Hartke T V, Borzan J, Klein AH, Turnquist B, Dong X, Meyer RA, Ringkamp M.
35 Three functionally distinct classes of C-fibre nociceptors in primates. *Nat Commun* 2014;5:4122.
36 doi:10.1038/ncomms5122.
- 37

1 [90] Zylka MJ, Rice FL, Anderson DJ. Topographically distinct epidermal nociceptive circuits revealed by
2 axonal tracers targeted to Mrgprd. *Neuron* 2005;45:17–25. doi:10.1016/j.neuron.2004.12.015.

3 4 **Figure legends**

5
6 **Figure 1: Flowchart of study procedures and treatment areas. A)** Sensory and vasomotor responses
7 were conducted according to the sketch. Heat pain thresholds and suprathreshold heat pain sensitivity for
8 all areas (A1-A4) were measured before provocation, while assessments were made individually after
9 each provocation. Notice that both the order of the 8% capsaicin and vehicle patches (pretreatment) and
10 compound application (provocation) (AITC 10% and capsaicin 1%) were randomized. **B)** Illustration of
11 treatment areas on the volar aspects of the forearms (example). Note that areas were randomized.
12 Abbreviations: AITC = Allyl isothiocyanate, CAP = Capsaicin, FLPI = Full-Field Laser-speckle
13 Perfusion Imaging, HPT = Heat pain threshold, NRS = Numerical rating scale (pain intensity), SHPS =
14 Suprathreshold heat pain sensitivity, VAS = Visual analogue scale (pain intensity).

15
16 **Figure 2: Evoked pain during administration of 8% capsaicin patch.** Evoked pain during the first 6 h
17 of application is shown for each forearm. Dashed lines indicate 24 h retrospectively rated average (lower)
18 and peak (upper) pain intensities. Abbreviations: NRS = Numerical rating scale. Means \pm SEMs are
19 shown.

20
21 **Figure 3: Pain evoked by provocations with CAP 1% and AITC 10%.** Mean pain intensities are
22 shown over time for **A)** CAP 1% and **B)** AITC 10%. Dashed lines represent mean and peak pain
23 intensities. 8% capsaicin induced sensory desensitization for CAP 1% and AITC 10% on **C)** peak, and **E)**
24 mean pain intensities. %-changes in **D)** for peak pain and **F)** for mean pain intensities following
25 capsaicin-ablation for CAP 1% and AITC 10%. Individual subjects (white dots) and mean (grey dots).
26 Notice that **C-F** share legends. Abbreviations: AITC = Allyl isothiocyanate, CAP = Capsaicin, VAS =
27 Visual analog scale. Means \pm SEMs are shown. Asterisks: *** $P < 0.001$.

28
29 **Figure 4. Heat pain sensitivity before and after provocation by CAP 1% and AITC 10% in vehicle-**
30 **and capsaicin-ablated areas. A)** Heat pain thresholds in capsaicin-ablated (grey) and vehicle-pretreated
31 (white) skin area for both CAP 1% and AITC 10%. **B)** Suprathreshold heat pain sensitivity in capsaicin-
32 ablated (grey) and vehicle-pretreated (white) skin area for both CAP 1% and AITC 10%. **C)** Change in
33 HPT following application of CAP 1% and AITC 10%. **D)** Change in SHPS following application of
34 CAP 1% and AITC 10%. Abbreviations: AITC = Allyl isothiocyanate, CAP = Capsaicin, NRS =

1 Numerical rating scale. Means \pm SEMs are shown (**A** and **B**) and means (**C** and **D**). Asterisks: ** $P < 0.01$
2 and *** $P < 0.001$.

3

4 **Figure 5. Representative superficial blood perfusion readouts.** Four images from 5 different subjects
5 following provocation by CAP 1% and AITC 10% in vehicle- and capsaicin-ablated skin areas. Notice
6 almost complete inhibition of neurogenic inflammation, with only very slight increases in perfusion
7 corresponding to the Finn chamber application area in two subjects shown in the upper panels. Black
8 quadrant in lower left corner marks the treatment area while the black circle marks the provocation
9 administration area. Abbreviations: AITC = Allyl isothiocyanate (10%), Arb. = Arbitrary, CAP =
10 Capsaicin (1%).

11

12 **Figure 6. Neurogenic inflammation and axon-reflex-flare evoked by CAP 1% and AITC 10% in**
13 **vehicle- and capsaicin-ablated skin areas. A)** Mean and peak superficial blood perfusion in capsaicin
14 pretreated (grey) and vehicle-pretreated (white) skin areas. **B)** Axon-reflex-flare size. **C)** Spatial extent of
15 of superficial blood perfusion following chemical provocations in capsaicin-ablated (dark grey and black)
16 and vehicle-pretreated skin (white and light grey). X-axis depicts the longitudinal distribution of the flare
17 reaction. Abbreviations: AITC = Allyl isothiocyanate, CAP = Capsaicin, arb = Arbitrary, cm =
18 Centimeter. Means \pm SEMs are shown. Asterisks: * $P < 0.05$ and *** $P < 0.001$.

19

20 **Figure 7. Z-score plot for mean and peak evoked pain, heat pain, antihyperalgesia, and axon-reflex**
21 **flare size for CAP 1% and AITC 10%.** Negative values represent desensitization effect (i.e. reduced
22 responses in treated skin). Note that the two chemical provocations only differ with respect to HPT
23 (driven by differences in vehicle-treated skin area). HPT = Heat pain threshold, SHPS = Suprathreshold
24 heat pain sensitivity. Means \pm SEMs are shown.

25

26 **Table legends**

27



28 **Table 1. Correlational analysis.** Significant correlations are marked in grey. V= vehicle area, A= ablated
29 area. P-values are multiplicity corrected by the Holm-Sidak method. An isolated correlational analysis of
30 mean perfusion data was performed to retain power. Asterisks: * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.


31

32


	1. Mean pain cap 8% (24h)	2. Mean pain CAP 1% (V)	3. ΔCAP 1% pain (V – A)	4. Mean pain AITC 10% (V)	5. ΔAITC 10% pain (V – A)	6. Mean pre-SHPS (V)		8. Mean perf. CAP 1% (V)
2. Mean pain CAP 1% (V)	$r = 0.676$ $* P = 0.027$						9. Mean perf. AITC 10% (V)	$r = 0.756$ $*** P < 0.001$
3. ΔCAP 1% pain (V – A)	$r = 0.665$ $* P = 0.029$	$r = 0.989$ $*** P < 0.001$						
4. Mean pain AITC 10% (V)	$r = 0.367$ $P = 0.293$	$r = 0.475$ $P = 0.284$	$r = 0.441$ $P = 0.293$					
5. ΔAITC 10% pain (V – A)	$r = 0.369$ $P = 0.293$	$r = 0.470$ $P = 0.284$	$r = 0.433$ $P = 0.293$	$r = 0.984$ $*** P < 0.001$				
6. Mean pre-SHPS (V)	$r = 0.849$ $*** P < 0.001$	$r = 0.702$ $* P = 0.016$	$r = 0.669$ $* P = 0.029$	$r = 0.386$ $P = 0.293$	$r = 0.435$ $P = 0.293$			
7. ΔSHPS (V – A)	$r = 0.577$ $P = 0.094$	$r = 0.642$ $* P = 0.040$	$r = 0.625$ $* P = 0.049$	$r = 0.416$ $P = 0.293$	$r = 0.427$ $P = 0.293$	$r = 0.722$ $** P = 0.01$		





ACCEPTED







ACCEPTED








ACCEPTED



ACCEPTED



ACCEPTED